{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06413511",
            "orgStudyIdInfo": {
                "id": "221615"
            },
            "organization": {
                "fullName": "GlaxoSmithKline",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study on the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Patients Aged 18 to 75 With Moderate to Severe Lupus",
            "officialTitle": "A Early-phase, Dose Escalation, Open Label Study to Evaluate the Safety, Tolerability, Drug Level Monitoring and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Participants With Moderate to Severe Lupus",
            "therapeuticArea": [
                "Immunology and Rheumatology"
            ],
            "study": "a-study-on-the-safety-and-pharmacological-effect-of-a-single-intravenous-infusion-of-belantamab-in-male-and-female-patients-aged-to-with-moderate-to-severe-lupus"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-03",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-11-27",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-11-27",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-09",
            "studyFirstSubmitQcDate": "2024-05-09",
            "studyFirstPostDateStruct": {
                "date": "2024-05-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "GlaxoSmithKline",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to assess the safety and tolerability profile of belantamab. The study will also assess how the levels of belantamab change over time and body's reaction to it in patients with moderate to severe systemic lupus erythematosus (SLE)."
        },
        "conditionsModule": {
            "conditions": [
                "Systemic Lupus Erythematosus"
            ],
            "keywords": [
                "Systemic Lupus Erythematosus",
                "Belantamab (GSK2857914)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 16,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Belantamab",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Biological: Belantamab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "Belantamab",
                    "description": "Belantamab will be administered.",
                    "armGroupLabels": [
                        "Belantamab"
                    ],
                    "otherNames": [
                        "GSK2857914"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with adverse events (AEs) and serious adverse events (SAEs)",
                    "timeFrame": "Up to Week 12"
                },
                {
                    "measure": "Number of participants with clinically important findings in vital signs",
                    "timeFrame": "Up to Week 12"
                },
                {
                    "measure": "Number of participants with clinically important findings in electrocardiogram",
                    "timeFrame": "Up to Week 12"
                },
                {
                    "measure": "Number of participants with clinically important findings in echocardiogram",
                    "timeFrame": "Up to Week 12"
                },
                {
                    "measure": "Number of participants with clinically important findings in haematology",
                    "timeFrame": "Up to Week 12"
                },
                {
                    "measure": "Number of participants with clinically important findings in clinical chemistry",
                    "timeFrame": "Up to Week 12"
                },
                {
                    "measure": "Number of participants with clinically important findings in urinalysis parameters",
                    "timeFrame": "Up to Week 12"
                },
                {
                    "measure": "Number of participants with clinically important findings in corneal toxicity",
                    "timeFrame": "Up to Week 12"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change from baseline in anti-double stranded deoxyribonucleic acid (anti-dsDNA) autoantibodies",
                    "timeFrame": "Baseline (Day 1) and at Week 6"
                },
                {
                    "measure": "Area under the concentration-time curve from time 0 to the last quantifiable concentration [AUC(0-t)] of belantamab",
                    "timeFrame": "Up to 12 weeks"
                },
                {
                    "measure": "Area under the concentration-time curve from time 0 to infinity [AUC(0-inf)] of belantamab",
                    "timeFrame": "Up to 12 weeks"
                },
                {
                    "measure": "Maximum observed plasma drug concentration [Cmax] of belantamab",
                    "timeFrame": "Up to 12 weeks"
                },
                {
                    "measure": "Number of participants with Anti-Drug Antibodies (ADAs) against belantamab",
                    "timeFrame": "Up to 12 weeks"
                },
                {
                    "measure": "Titers of ADAs against belantamab",
                    "timeFrame": "Up to 12 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Body mass index (BMI) from 18 to 32 kilograms per square meter (kg/m\u00b2) (BMI = weight/height\\^2), inclusive, and body weight of \u226540 kg\n* Documented clinical diagnosis of SLE according to the European League Against Rheumatism (EULAR) or American College of Rheumatology (ACR) Classification Criteria\n* Moderate to Severe SLE disease\n* Positive anti-dsDNA autoantibody test results\n* Sex and Contraceptive/Barrier requirements for males and females\n\nExclusion Criteria:\n\n* Any acute, severe lupus related flare during the Screening Period that needs immediate treatment\n* Has any unstable or progressive manifestation of SLE\n* Significant, likely irreversible organ damage related to SLE\n* Major Diseases/Conditions/Morbidities including participants with any uncontrolled medical conditions (other than SLE) that in the opinion of the investigator puts the participant at unacceptable risk",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "US GSK Clinical Trials Call Center",
                    "role": "CONTACT",
                    "phone": "877-379-3718",
                    "email": "GSKClinicalSupportHD@gsk.com"
                },
                {
                    "name": "EU GSK Clinical Trials Call Center",
                    "role": "CONTACT",
                    "phone": "+44 (0) 20 89904466",
                    "email": "GSKClinicalSupportHD@gsk.com"
                }
            ],
            "locations": [
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Medley",
                    "state": "Florida",
                    "zip": "33166",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Ramon Moreda",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.84065,
                        "lon": -80.32644
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Peachtree Corners",
                    "state": "Georgia",
                    "zip": "30071",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Darrell Murray",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.9701,
                        "lon": -84.22159
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR"
            ],
            "timeFrame": "Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.",
            "accessCriteria": "Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",
            "url": "https://www.gsk.com/en-gb/innovation/trials/data-transparency/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008180",
                    "term": "Lupus Erythematosus, Systemic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11177",
                    "name": "Lupus Erythematosus, Systemic",
                    "asFound": "Systemic Lupus Erythematosus",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}